X4 Pharmaceuticals, Inc. (XFOR)

Verve Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	40.26	55.7	99.22	121.72	81.79	78.71
Short-Term Investments	46.69	46.36	15	-	-	-
Cash & Short-Term Investments	86.95	102.06	114.22	121.72	81.79	78.71
Cash Growth	7.52%	-10.64%	-6.16%	48.82%	3.91%	-37.62%
Accounts Receivable	0.51	1.07	-	-	-	-
Other Receivables	0.67	0.64	0.56	1.15	0.75	0.92
Receivables	1.17	1.71	0.56	1.15	0.75	0.92
Inventory	3.09	2.82	-	-	-	-
Prepaid Expenses	4.48	5.59	7.05	5.52	5.34	3.42
Restricted Cash	-	-	0.25	0.29	-	0.26
Total Current Assets	95.7	112.18	122.08	128.68	87.88	83.31
Property, Plant & Equipment	4.14	4.84	6.4	8.33	10.22	9.2
Goodwill	17.35	17.35	17.35	17.35	17.35	27.11
Other Intangible Assets	9.81	10	-	-	-	-
Other Long-Term Assets	3.01	2.08	1.44	1.23	1.72	3.26
Total Assets	130.01	146.45	147.26	155.59	117.18	122.87
Accounts Payable	11.12	8.62	8.95	7.78	4.28	3.14
Accrued Expenses	12.61	23.01	12.82	11.44	7.85	8.02
Current Portion of Long-Term Debt	-	-	-	1.32	0.8	-
Current Portion of Leases	1.3	1.25	1.1	1.2	1.08	0.79
Other Current Liabilities	-	-	-	0.59	0.03	-
Total Current Liabilities	25.88	32.88	22.86	22.32	14.02	11.95
Long-Term Debt	75.63	75.43	54.57	32.3	33.14	33.18
Long-Term Leases	1.11	1.41	2.61	3.6	4.78	4.48
Other Long-Term Liabilities	3.49	14.59	16.12	23.3	0.83	0.46
Total Liabilities	107.07	124.3	96.16	81.54	52.76	50.07
Common Stock	0.01	0.17	0.17	0.12	0.03	0.02
Additional Paid-In Capital	538.14	537.46	528.96	450.79	347.37	267.08
Retained Earnings	-515.07	-515.36	-477.91	-376.74	-282.87	-194.18
Comprehensive Income & Other	-0.13	-0.12	-0.12	-0.12	-0.12	-0.12
Total Common Equity	22.94	22.15	51.1	74.05	64.41	72.8
Shareholders' Equity	22.94	22.15	51.1	74.05	64.41	72.8
Total Liabilities & Equity	130.01	146.45	147.26	155.59	117.18	122.87
Total Debt	78.04	78.09	58.28	38.42	39.79	38.45
Net Cash (Debt)	8.91	23.97	55.94	83.3	42	40.26
Net Cash Growth	-60.57%	-57.14%	-32.85%	98.32%	4.33%	-61.02%
Net Cash Per Share	1.32	3.58	9.44	39.34	48.94	60.16
Filing Date Shares Outstanding	5.79	5.79	5.6	4.07	1.03	0.58
Total Common Shares Outstanding	5.79	5.7	5.58	4.06	0.94	0.54
Working Capital	69.81	79.3	99.21	106.35	73.86	71.36
Book Value Per Share	3.96	3.89	9.16	18.26	68.70	133.94
Tangible Book Value	-4.22	-5.2	33.75	56.7	47.06	45.69
Tangible Book Value Per Share	-0.73	-0.91	6.05	13.98	50.19	84.06
Machinery	2.47	2.43	2.11	2.08	1.98	1.25
Leasehold Improvements	0.23	0.23	0.23	0.23	0.23	0.23

Updated May 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q